Will Teriparatide rebuild bone density in young women at 29?

Question

Hello doctor,

My mother is 67 years old, and her most recent DEXA scan revealed a T-score of minus 3.2 at the lumbar spine and minus 2.8 at the femoral neck, which her GP mentioned places her in the severe osteoporosis category with an extremely high fracture risk.

She has been on Alendronate 70 mg weekly for nearly three years, but recently suffered a hairline vertebral fracture at T12 despite this ongoing treatment, suggesting that her current medication may not be adequately protecting her worsening bone density.

Will Teriparatide help rebuild bone density in younger women, such as at 29 years of age, and could this same anabolic treatment approach also be appropriately considered for my mother at 67, who has clearly not responded adequately to three years of bisphosphonate therapy?
Can a general physician urgently evaluate whether switching to Teriparatide 20 mcg daily or Romosozumab 210 mg monthly would provide significantly better bone rebuilding outcomes than continuing her current oral treatment regimen?

Please help.

Thank you.

Answer 1

Hello,

Welcome to icliniq.com.

I have gone through your query and understand your concern.

Your mother’s situation does sound concerning, especially because she has sustained a vertebral fracture despite nearly three years of treatment with Alendronate.

A lumbar spine T-score of minus 3.2, together with a fragility fracture, places her in what many specialists would consider a very high fracture-risk osteoporosis category. In that setting, it is reasonable for her physicians to consider whether continuing the same oral bisphosphonate is enough.

Treatments such as Teriparatide and Romosozumab are anabolic therapies, meaning they actively stimulate new bone formation rather than mainly slowing bone breakdown as Alendronate does.

Teriparatide has been shown to increase bone mineral density and reduce vertebral fracture risk in both younger patients with severe osteoporosis and older adults, including women in their late 60s and beyond. Romosozumab can sometimes produce even faster gains in bone density, particularly in the spine, though it must be used carefully in people with certain cardiovascular histories.

In clinical practice, when a patient fractures while remaining adherent to bisphosphonate therapy, physicians often reassess for what is considered treatment failure or an inadequate response.

That evaluation usually includes confirming medication adherence, checking vitamin D and calcium status, ruling out secondary causes of osteoporosis such as hyperparathyroidism, thyroid disease, malabsorption, chronic steroid exposure, or multiple myeloma, and reviewing repeat DEXA (dual energy X-ray absorptiometry) scan trends.

If those factors are addressed and fracture risk remains very high, switching to an anabolic agent is absolutely something many endocrinologists or osteoporosis specialists would consider. In fact, for someone with severe osteoporosis plus a new vertebral fracture, anabolic therapy is often favored over simply continuing the same oral regimen.

After completing anabolic treatment, patients are usually transitioned back to an antiresorptive medication to help preserve the newly built bone.

I hope I have answered your question.

Let me know if I can assist you further.

Thank you.